Immune Checkpoint Inhibitors in Hepatocellular Carcinoma: Current Strategies and Biomarkers Predicting Response and/or Resistance

In recent years, immune checkpoint inhibitors (ICIs) have revolutionized the treatment of patients with hepatocellular carcinoma (HCC). Following the positive results of the IMbrave150 trial, the combination of atezolizumab (an anti-PD-L1 antibody) and bevacizumab (an anti-VEGF antibody) became the...

Descripción completa

Detalles Bibliográficos
Autores principales: Pelizzaro, Filippo, Farinati, Fabio, Trevisani, Franco
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10135644/
https://www.ncbi.nlm.nih.gov/pubmed/37189643
http://dx.doi.org/10.3390/biomedicines11041020

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10135644/
https://www.ncbi.nlm.nih.gov/pubmed/37189643
http://dx.doi.org/10.3390/biomedicines11041020

Ejemplares similares